Fate Therapeutics, Inc. FATE 深 滬
等待開盤 04-02 09:30:00 美东时间
1.24
+0.040
+3.33%
華盛通- 最 高1.265
- 今 開1.22
- 成交量 70.73万股
- 最 低 1.22
- 昨 收 1.20
- 總市值 1.44亿
- 52周最高 1.9399
- 市盈率 靜 --
- 換手率 0.61%
- 52周最低 0.8651
- 委 比 45.76%
- 總股本 1.16亿
- 歷史最高 121.16
- 量 比 0.52
- 振 幅 3.75%
- 歷史最低 0.6611
- 每 手 1
- 風險率 0.18%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Scalable Biotech Manufacturing Unlocks a $14B Market
Issued on behalf of Avaí Bio, Inc. VANCOUVER, BC, March 27, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary — The global cell therapy manufacturing market is hitting a pivotal inflecti...
03-27 21:15
Earnings Summary: Fate Therapeutics Q4
Fate Therapeutics (NASDAQ:FATE) just disclosed its Q4 earnings on Thursday, Feb...
02-26 22:06
Fate Therapeutics Q4 EPS $(0.27) Misses $(0.26) Estimate, Sales $1.369M Beat $1.186M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.26) by 3.85 percent. This is a 38.64 percent increase over losses of $(0.44) per share
02-26 22:05
Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets
Issued on behalf of Avant Technologies Inc. Equity Insider News Commentary VANCOUVER, BC, Jan. 26, 2026 /PRNewswire/ -- The medical world is shifting as the global market for next-gen treatm...
01-26 23:16
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics, Inc. granted stock options and RSUs to new employees. A total of 48,000 stock options and 79,400 RSUs were awarded, vesting over four years under the Inducement Equity Plan. This was approved by the Compensation Committee to attract new hires, aligning with Nasdaq Listing Rule 5635(c)(4).
01-05 21:05
Fate Therapeutics Presents Updated Clinical Data From Its Ongoing Phase 1 Trial Evaluating Its Ft819 Off-The-Shelf iPSC-derived Car T-cell Program In Systemic Lupus Erythematosus And Unveiled New Preclinical Data From Next-Gen. Off-The-Shelf iPSC-Derived Car T-cell Programs For Hematologic Malignancies And Autoimmune Diseases At 2025 American Society Of Hematology Annual Meeting
FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now treated; first systemic sclerosis (SSc) patient treatedFirst ex-U.S.
2025-12-08 21:12
Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference
Fate Therapeutics, a clinical-stage biopharmaceutical company focused on developing iPSC-derived cellular immunotherapies for cancer and autoimmune diseases, announced its participation in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York. The company’s management will engage in a fireside chat at 9:00 AM ET and a cell therapy panel discussion at 12:00 PM ET. Both presentations will be available live via webcast...
2025-11-25 13:00
Fate Therapeutics Reports Q3 Loss Amid Restructuring Efforts
Fate Therapeutics Inc ( ($FATE) ) has released its Q3 earnings. Here is a break...
2025-11-18 11:55
Fate Therapeutics Q3 EPS $(0.27) Beats $(0.29) Estimate, Sales $1.741M Beat $1.535M Estimate
Fate Therapeutics (NASDAQ:FATE) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.29) by 6.9 percent. This is a 32.5 percent increase over losses of $(0.40) per share from
2025-11-13 21:41
Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates
Fate Therapeutics reported third-quarter 2025 financial results, including $225.7 million in cash, $1.7 million in revenue, and $36.5 million in operating expenses. The company highlighted progress in its FT819 CAR T-cell program for autoimmune diseases, including regulatory approvals in the UK and EU, and favorable clinical data. It also announced the first patient treated with FT836, a MICA/B-targeted CAR T-cell therapy, and Initiation of IND a...
2025-11-13 13:30
